Novartis AG
NYSE:NVSDrug Manufacturers - General
-$3.38 today
- Market cap
- $293.13B
- Beta
- 0.49
- P/E (TTM)
- 20.7
- EPS (TTM)
- $7.06
- Dividend yield
- 3.13%
Volume 2.75M
Average 1.56M
NVS EBITDA Margin
EBITDA as a percentage of revenue.
Novartis AGNYSE: NVS
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin holds steady near 41.2%
EBITDA Margin was 41.2% in Q2 FY2026, up 0.2 pp from a year earlier. On a trailing-twelve-month basis it was 40.0%, down 1.1 pp year over year. Over 3 fiscal years it widened by 8.2 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 12 analysts of 42.8% for the fiscal year ending Dec 2026, up from 41.9% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 41.2%+1.2 pp QoQ
- Last fiscal yearDec 2025
- 41.9%+1.9 pp YoY
- LTMJun 2026
- 40.0%-1.1 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +0.2 pp | +19.0 pp | +18.8 pp |
| 1 year | +1.9 pp | +0.9 pp | -1.0 pp |
| 3 years | +8.2 pp | +1.2 pp | -7.0 pp |
| 5 years | +3.3 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 41.9%
- Year-over-year change
- +1.9pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.9% | +1.9pp |
| FY2024 | 2024-12-31 | 40.1% | +0.9pp |
| FY2023 | 2023-12-31 | 39.1% | +5.3pp |
| FY2022 | 2022-12-31 | 33.8% | -36.5pp |
| FY2021 | 2021-12-31 | 70.3% | — |
EBITDA Margin vs competitors
How NVS compares with its peers on the latest reported figures
- NVS's LTM Jun 2026 EBITDA Margin of 40.0% is the 2nd highest of the 11 companies compared; the peer median is 30.6%.
- Its year-over-year change of -1.1 pp is the 7th highest of 11, against a peer median of -0.6 pp.
- Over three fiscal years its change of +8.2 pp compares with a peer median of +4.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 54.9% | -0.5 pp | +7.3 pp | |
| LTM Jun 2026 | 40.0% | -1.1 pp | +8.2 pp | |
| LTM Sep 2026 | 36.6% | +15.1 pp | -12.8 pp | |
| LTM Sep 2026 | 34.4% | +3.4 pp | +13.3 pp | |
| LTM Jun 2026 | 34.2% | +2.6 pp | -10.0 pp | |
| LTM Sep 2026 | 31.0% | -11.9 pp | +10.3 pp | |
| LTM Jun 2026 | 30.2% | +0.6 pp | -6.6 pp | |
| LTM Jun 2026 | 26.5% | -0.7 pp | +2.5 pp | |
| LTM Jun 2026 | 21.2% | -10.4 pp | -13.7 pp | |
| LTM Jun 2026 | 21.0% | -18.3 pp | +7.6 pp | |
| LTM Jun 2026 | 4.4% | -33.6 pp | +13.7 pp | |
| Peer median (excluding NVS) | 30.6% | -0.6 pp | +4.9 pp | |
Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 43.97B | 43.46B | 46.66B | 51.72B | 54.81B |
| Cost of Revenue | 11.74B | 11.58B | 12.47B | 12.83B | 13.69B |
| Gross Profit | 32.24B | 31.88B | 34.19B | 38.9B | 41.12B |
| Gross Margin | 73.3% | 73.4% | 73.3% | 75.2% | 75.0% |
| Research & Development | 8.64B | 9.17B | 11.37B | 10.02B | 10.74B |
| Selling, General & Admin | 12.83B | 12.19B | 12.52B | 12.57B | 13.31B |
| Operating Expenses | 22.18B | 23.93B | 24.42B | 24.35B | 24.05B |
| Depreciation & Amortization | 5.6B | 6.71B | 8.28B | 6.07B | 5.35B |
| EBITDA | 30.91B | 14.68B | 18.26B | 20.72B | 22.99B |
| EBITDA Margin | 70.3% | 33.8% | 39.1% | 40.1% | 41.9% |
| Operating Income | 10.06B | 7.95B | 9.77B | 14.54B | 17.07B |
| Operating Margin | 22.9% | 18.3% | 20.9% | 28.1% | 31.2% |
| Interest Income | 71M | 377.74M | 629.24M | 567.68M | 374.91M |
| Interest Expense | 905M | 834.62M | 876.12M | 1.04B | 1.19B |
| Other Income / Expenses | 14.47B | (769M) | (646M) | (904M) | (638.25M) |
| Income Before Tax | 24.53B | 7.18B | 9.12B | 13.64B | 16.44B |
| Pre-Tax Margin | 55.8% | 16.5% | 19.6% | 26.4% | 30.0% |
| Income Tax Expense | 1.63B | 1.13B | 551M | 1.7B | 2.4B |
| Net Income | 24.02B | 6.96B | 14.85B | 11.94B | 14.06B |
| Net Margin | 54.6% | 16.0% | 31.8% | 23.1% | 25.6% |
| EPS (Basic) | 10.71 | 3.19 | 7.15 | 5.92 | 7.25 |
| EPS (Diluted) | 10.63 | 3.17 | 7.10 | 5.87 | 7.19 |
| Weighted Avg Shares | 2.24B | 2.18B | 2.08B | 2.02B | 1.94B |
| Weighted Avg Shares (Diluted) | 2.26B | 2.2B | 2.09B | 2.04B | 1.96B |
Novartis AG
NYSE:NVS
Intrinsic Alpha fair value
Locked
Current Price
$155.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.